The presence of tumour-activated CD8+ TILs is an essential requirement for the treatment with immune checkpoint inhibitors, while PD-L1 expression has been shown to be associated with improved outcomes upon immunotherapy [24]. This evidence concerns the gene CD8A and neoplasm.